CD200 is a new prognostic factor in multiple myeloma.
Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMCs) of 112 patients with newly diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMCs, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200(absent) MMCs have an increased event-free survival (EFS; 24 months) compared with patients with CD200(present) MMCs (14 months), after high-dose therapy and stem cell transplantation. In a Cox proportional-hazard model, the absence or presence of CD200 expression in MMCs is predictive for EFS for patients independently of ISS stage or beta2M serum levels. Thus, CD200 is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM.
Moreaux
Jerome
J
Centre Hospitalier Universitaire (CHU) Montpellier, Department of Hematology and Clinical Oncology and Institute of Research in Biotherapy, Montpellier, France.
Hose
Dirk
D
Reme
Thierry
T
Jourdan
Eric
E
Hundemer
Michael
M
Legouffe
Eric
E
Moine
Philippe
P
Bourin
Philippe
P
Moos
Marion
M
Corre
Jill
J
Möhler
Thomas
T
De Vos
John
J
Rossi
Jean Francois
JF
Goldschmidt
Hartmut
H
Klein
Bernard
B
D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis
D015703:Antigens, CD; D014408:Biomarkers, Tumor; C042739:antigens, CD200